Navigation Links
The Crohn's & Colitis Foundation of America and Shire Launch Virtual 'IBD March on the Hill' to Increase Funding for Digestive Disease Research
Date:5/6/2009

/supportccfa) and now we're asking supporters to join us 'virtually' in DC. With this community support, we are one step closer to increasing education and research for IBD."

After the 30,000 steps have been reached, the program will continue to generate awareness of CCFA's efforts to rally advocates to increase awareness of IBD.

"We are excited to work with CCFA to launch an innovative program that engages IBD patients, friends and family members through social networking to increase IBD awareness and research," said Roger Adsett, senior vice president of Shire's gastrointestinal business unit. "We hope this program will continue to demonstrate our commitment to providing education to the IBD patient community and support for CCFA's advocacy efforts on Capitol Hill."

For more information on the virtual "IBD March on the Hill" or CCFA's "IBD Day on the Hill," visit www.ccfa.org.

For further information please contact:

    Media    Sarah McGee (GolinHarris)                        +1 312 729 4125
             Matthew Cabrey (Shire)                           +1 484 595 8248
             Ariella Levine (Crohn's & Colitis Foundation)    +1 646 943 7430

About Crohn's Disease & Ulcerative Colitis

Crohn's disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn's
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis
2. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
3. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
4. Elsevier and Brain Mapping Foundation Co-Host 6th Annual World Congress of IBMISPS on Brain Mapping and Image Guided Therapy
5. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
6. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
7. Mirixa Corporation and the APhA Foundation Finalize Partnership
8. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
9. Peter Zoller and Ignacio Cirac, awarded by the BBVA Foundation
10. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
11. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... RainDance Technologies, Inc., a,provider of innovative microdroplet-based ... the relocation of the company from,Guilford, Connecticut, to ... facility and start up commercial and manufacturing operations,effective ... our first life sciences application scheduled for,the fourth ...
... Epeius Biotechnologies,announced today the results of an on-going ... et al., ASCO meeting, 2008).,Continuing on with the planned ... of Rexin-G in a Phase I safety study (Molecular,Therapy, ... Rexin-G given i.v. two to three times a week ...
... Replikins Ltd. has found that very high,concentrations ... the,trypanosomes that are the infectious agents in malaria. ... the highest replikin concentrations observed to,date in any ... that these,concentrations cycle over several years., Replikins ...
Cached Biology Technology:RainDance Announces Company Relocation and Manufacturing Startup 2ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer 2Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes 2
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... first time, large-scale information on the biochemical makeup ... publicly. These molecules are used in research to ... disease. Making these data accessible to researchers worldwide ... patients. NIH,s National Center for Advancing ...
... As coastal communities continue to rebuild in the ... meeting of the American Geophysical Union offer some encouraging ... barrier system that controls erosion on Long Island. Long-term ... sea-level rise, pollutants churned up by the storm within ...
... , Dec. 10, 2013  KaloBios Pharmaceuticals, Inc. ... results of an ongoing multi-center Phase 1 study ... company is developing as a treatment for hematologic ... were unfit for chemotherapy have been enrolled in ...
Cached Biology News:Gene-silencing data now publicly available to help scientists better understand disease 2Gene-silencing data now publicly available to help scientists better understand disease 3Post-Sandy, Long Island barrier systems appear surprisingly sound 2Post-Sandy, Long Island barrier systems appear surprisingly sound 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 4KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 5
... Acetate: CoA ligase (AMP forming), Acetate ... on protein content. Physical form: ... sucrose and reduced glutathione Preparation ... mol of S-acetyl coenzyme A from acetate, ...
...
... 15(S)-15-methyl PGF2α is a ... It is a potent uterine ... be administered intramuscularly to induce ... reduces serum progesterone concentrations when ...
... Biochem/physiol Actions: Glutathione-S-transferases (GSTs) are a group ... many xenobiotics in mammals. The enzymes ... thiol group of the glutathione to electrophilic ... mutagenic, carcinogenic, and toxic effects of the ...
Biology Products: